Quantcast

Latest Sedatives Stories

2008-09-18 18:00:19

NovaDel Pharma Inc. (AMEX: NVD) today announced that the U.S. Food and Drug Administration (FDA) has requested an extension of up to 3 months on the Prescription Drug User Fee Act (PDUFA) deadline in order to complete the review of the Company's Zolpimist (zolpidem tartrate) Oral Spray for the short-term treatment of insomnia. Based on the original PDUFA date for Zolpimist, the FDA will reply on or before December 19, 2008. "We believe we have submitted a high quality 505(b)(2) application...

2008-09-09 15:00:09

-- Elderly patients taking LUNESTA 2 mg showed significant improvements in measures of daytime function compared to placebo over a 12-week treatment period -- Elderly patients administered LUNESTA 2 mg showed no evidence of rebound insomnia and withdrawal symptoms were comparable to the placebo group upon discontinuation Sepracor Inc. Jonae R. Barnes, 508-481-6700 Sr. Vice President, Investor Relations & Corporate Communications Sepracor Inc. (Nasdaq: SEPR) today announced the...

2008-09-03 18:00:41

Using functional magnetic resonance imaging, Dutch researchers said cognitive deficits were reversed after six weeks of sleep therapy. The study, published in the journal Sleep, found that cognitive processes related to verbal fluency are compromised in people with insomnia despite the absence of a behavioral deficit. However, these specific brain function alterations can be reversed through non-pharmacological treatment with sleep therapy, the study said. The study authors suggest sleep...

2a2042e68ca30705bcfa50794e7456f5
2008-09-03 13:17:57

Analysts in the UK have reported a surge in popularity of the drug diazepam, better known as Valium, among drug users. According to independent drug research organization DrugScope, diazepam use as a heroin substitute is increasing among drug users in 15 out of 20 towns it surveyed. Known on the street as "Ëœblues' of "Ëœvallies', Valium is a class C drug, but experts are concerned about the rise in its use among class A drug users over the past 12 months. DrugScope...

2008-09-03 09:00:08

Sepracor Inc. (Nasdaq: SEPR) today announced the presentation of LUNESTA(R) brand eszopiclone Phase IV study data at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. The poster presentations reflected results from a 12-week, double-blind, randomized safety and efficacy study of 388 elderly patients (65-85 years of age) who were administered either LUNESTA 2 mg or placebo nightly. Upon conclusion of the 12-week, double-blind treatment period, all patients...

2008-09-02 18:00:30

Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, today announced that data from a pharmacological profiling study relating to doxepin, the active ingredient in the company's product candidate Silenor for the treatment of insomnia, were presented yesterday at the 21st European College of...

2008-09-02 03:00:33

Novacea, Inc. (NASDAQ: NOVC) and Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that they have entered into a definitive merger agreement under which Novacea will merge with Transcept in an all-stock transaction. Under the terms of the merger agreement, Novacea will issue new shares of its common stock to Transcept stockholders based on an exchange ratio to be determined prior to the closing of the transaction. Under the exchange ratio...

2008-08-18 15:05:00

SAN DIEGO, Aug. 18 /PRNewswire/ -- The next time you consider popping a pill when you have trouble nodding off, it might be worth counting sheep instead. A senior psychiatrist at the Scripps Clinic Sleep Center in San Diego, Calif. has found evidence that taking sleeping pills regularly can increase the risk of skin cancer. Daniel F. Kripke, M.D.'s article, based on a compilation of studies involving sleeping pills and cancer, has just been published in the Journal of Sleep Research. It...

2008-08-08 21:00:22

Britain plans to outlaw two freely available chemicals that double as date-rape drugs, the country's domestic security and order office said. Glue remover gamma-butyrolactone, known as GBL, and industrial solvent 1,4 butanediol, also known as "One Comma Four" or "One Four Bee," will be classified as Class C controlled substances that are illegal to sell or supply, the Home Office said. Britain first plans to ask the chemical industry for its views on controlling the chemicals -- which...

2008-08-01 12:01:08

Handa Pharmaceuticals has confirmed that its abbreviated new drug application for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR, has been accepted for filing by the FDA. Based upon available information, Handa believes that it is the first applicant to file an abbreviated new drug application (ANDA) for Seroquel XR containing a paragraph IV certification, under the provisions of the Hatch- Waxman Act. Should its ANDA be approved by the...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.